HLA-A*0201 & B2M & p53 (HMTEVVRHC)

HLA-A*0201 & B2M & p53 (HMTEVVRHC) Product List

  • Product Category

    Protein (2)

  • Product Status

    Launched (2)

  • Species

    Human (2)

  • Tag

    His Tag & Avi Tag (1)His Tag (1)

  • Conjugate

    Biotin-labeled (1)PE Labeled (1)

HLA-A*0201 & B2M & p53 (HMTEVVRHC) Background

TP53 has been recognized as a tumor suppressor. 50% of cancers carry a TP53 mutation while many others affect other pathway components. High-copy numbers of WT p53 peptide-MHC class I complexes were detected on tumor cells as compared to low copies on normal cells. The Human HLA-A*0201 p53 (HMTEVVRHC) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and HMTEVVRHC peptide of the p53.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Superoxide dismutase (Ube Industries)r-hSOD; FKU-871Phase 2 ClinicalUbe Industries Ltd, Astellas Pharma IncMyocardial Ischemia; Diabetic Neuropathies
Details
OtaplimastatSP-8203 hydrochloride; SP8203 HCL; SP-8203Phase 2 ClinicalShin Poong Pharmaceutical Co LtdStroke
Details
BMX-010BMX-010; MnTE-2-PyP; MnTE-2-PyP5+Phase 2 ClinicalDuke UniversityAcne Vulgaris; Rosacea; Psoriasis; Dermatitis, Atopic
Details
APB-102APB-102; AMT-162Phase 2 ClinicalUniversity Of Massachusetts Medical SchoolAmyotrophic Lateral Sclerosis
Details
Rucosopasem manganeseGC-4711Phase 1 ClinicalGalera Therapeutics IncPancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
Bis-choline tetrathiomolybdateATN-224; WTX-101; ALXN-1840Phase 1 ClinicalWilson TherapeuticsHepatolenticular Degeneration; Multiple Myeloma; Prostatic Neoplasms; Melanoma
Details
NAS150AEOL-10150; NAS150; NAS-150Phase 1 ClinicalAeolus PharmaceuticalsSupranuclear Palsy, Progressive; Idiopathic Pulmonary Fibrosis; Neoplasms; Lung Injury
Details
RAG-17RAG-17; RAG17Phase 1 ClinicalAmyotrophic Lateral Sclerosis
Details
NI-005AP-101 (AL-S Pharma); NI-005Phase 1 ClinicalAl-S Pharma AgAmyotrophic Lateral Sclerosis
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
OrgoteinApprovedGt Biopharma IncOntoseinSpainRheumatic Diseases; Cystitis; Radiation Injuriesnull1996-01-01Cystitis; Radiation Injuries; Rheumatic Diseases
Details
Cupric Sulfate/Manganese sulfate/Selenious acid/Zinc SulfateApprovedAmerican Regent IncMULTRYSUnited StatesDietary SupplementAmerican Regent Inc2020-07-02Dietary Supplement
Details
TofersenISIS-333611; BIIB-067; 99mTc-MAG3-BIIB067ApprovedLudwig Institute For Cancer Research, Ionis Pharmaceuticals IncQALSODYUnited StatesAmyotrophic Lateral SclerosisBiogen Ma Inc, Biogen Inc2023-04-25Amyotrophic Lateral Sclerosis
Details
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland